SEARCH:   Advanced

Prepublished online as a Blood First Edition Paper on May 13, 2002; DOI 10.1182/blood-2002-02-0377. This Article Full Text Full Text (PDF) All Versions of this Article: 2002-02-0377v1 100/5/1619    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Chakrabarti, S. Articles by Milligan, D. W. Search for Related Content PubMed PubMed Citation Articles by Chakrabarti, S. Articles by Milligan, D. W. Related Collections Transplantation Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, 1 September 2002, Vol. 100, No. 5, pp. 1619-1627 CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Adenovirus infections following allogeneic stem cell transplantation: incidence and outcome in relation to graft manipulation, immunosuppression, and immune recovery Suparno Chakrabarti, Vivien Mautner, Husam Osman, Kathryn E. Collingham, Chris D. Fegan, Paul E. Klapper, Paul A. H. Moss, and Donald W. Milligan From the Departments of Haematology and Public Health Laboratory, Birmingham Heartlands Hospital; and the Cancer Research UK Institute for Cancer Studies, University of Birmingham, United Kingdom; and the Department of Clinical Virology, Manchester Royal Infirmary, United Kingdom. Adenovirus infections occur in 5% to 21% of patients following stem cell transplantation (SCT), with an associated mortality of up to 50%. However, a lack of prospective studies has hampered further developments in the understanding and management of this infection in the posttransplantation setting. We prospectively studied the incidence and outcome of adenovirus infections after SCT using preemptive screening and a policy of reduction or withdrawal of immunosuppressive therapy if the virus was isolated. The incidence of adenovirus infection was 19.7% (15 of 76), and the virus was isolated exclusively in recipients of T-cell-depleted grafts. Patients receiving 50 or 100 mg alemtuzumab in vivo were at the greatest risk of adenovirus infection (45% probability) regardless of donor type, and this was related to the slower lymphocyte recovery. Six (40%) of the 15 adenovirus-infected patients developed adenovirus disease. Severe lymphocytopenia (less than 300/µL) at the time of first detection of adenovirus was a major risk factor for development of adenovirus disease (P = .001). In addition, failure to reduce immunosuppression (P = .04) and a positive result of adenovirus polymerase chain reaction (PCR) in blood at diagnosis (P = .01) were both associated with fatal adenovirus disease. On the basis of this study, we recommend active surveillance for adenovirus infection in T-cell-depleted SCT and withdrawal or reduction of immunosuppressive treatment, if possible, in patients with adenovirus infection. Preemptive antiviral therapy is warranted for patients with severe lymphocytopenia or positive blood PCR, and in those in whom immunosuppressive therapy cannot be reduced. © 2002 by The American Society of Hematology.   CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: Z. Zhu, Y. Zhang, S. Xu, P. Yu, X. Tian, L. Wang, Z. Liu, L. Tang, N. Mao, Y. Ji, et al. Outbreak of Acute Respiratory Disease in China Caused by B2 Species of Adenovirus Type 11 J. Clin. Microbiol., March 1, 2009; 47(3): 697 - 703. [Abstract] [Full Text] [PDF] A. Joshi, J. Tang, M. Kuzma, J. Wagner, B. Mookerjee, J. Filicko, M. Carabasi, N. Flomenberg, and P. Flomenberg Adenovirus DNA polymerase is recognized by human CD8+ T cells J. Gen. Virol., January 1, 2009; 90(1): 84 - 94. [Abstract] [Full Text] [PDF] K. Toth, J. F. Spencer, D. Dhar, J. E. Sagartz, R. M. L. Buller, G. R. Painter, and W. S. M. Wold Hexadecyloxypropyl-cidofovir, CMX001, prevents adenovirus-induced mortality in a permissive, immunosuppressed animal model PNAS, May 20, 2008; 105(20): 7293 - 7297. [Abstract] [Full Text] [PDF] L. Lenaerts, H. Kelchtermans, L. Geboes, P. Matthys, E. Verbeken, E. De Clercq, and L. Naesens Recovery of Humoral Immunity Is Critical for Successful Antiviral Therapy in Disseminated Mouse Adenovirus Type 1 Infection Antimicrob. Agents Chemother., April 1, 2008; 52(4): 1462 - 1471. [Abstract] [Full Text] [PDF] D. Onion, L. J. Crompton, D. W. Milligan, P. A. H. Moss, S. P. Lee, and V. Mautner The CD4+ T-cell response to adenovirus is focused against conserved residues within the hexon protein J. Gen. Virol., September 1, 2007; 88(9): 2417 - 2425. [Abstract] [Full Text] [PDF] M. Robin, S. Marque-Juillet, C. Scieux, R. P. de Latour, C. Ferry, V. Rocha, J.-M. Molina, A. Bergeron, A. Devergie, E. Gluckman, et al. Disseminated adenovirus infections after allogeneic hematopoietic stem cell transplantation: incidence, risk factors and outcome Haematologica, September 1, 2007; 92(9): 1254 - 1257. [Abstract] [Full Text] [PDF] R. G. Meyer, C. M. Britten, D. Wehler, K. Bender, G. Hess, A. Konur, U. F. Hartwig, T. C. Wehler, A. J. Ullmann, C. Gentilini, et al. Prophylactic transfer of CD8-depleted donor lymphocytes after T-cell-depleted reduced-intensity transplantation Blood, January 1, 2007; 109(1): 374 - 382. [Abstract] [Full Text] [PDF] B. Heemskerk, T. van Vreeswijk, L. A. Veltrop-Duits, C. C. Sombroek, K. Franken, R. M. Verhoosel, P. S. Hiemstra, D. van Leeuwen, M. E. Ressing, R. E. M. Toes, et al. Adenovirus-Specific CD4+ T Cell Clones Recognizing Endogenous Antigen Inhibit Viral Replication In Vitro through Cognate Interaction J. Immunol., December 15, 2006; 177(12): 8851 - 8859. [Abstract] [Full Text] [PDF] E. Seiradake, H. Lortat-Jacob, O. Billet, E. J. Kremer, and S. Cusack Structural and Mutational Analysis of Human Ad37 and Canine Adenovirus 2 Fiber Heads in Complex with the D1 Domain of Coxsackie and Adenovirus Receptor J. Biol. Chem., November 3, 2006; 281(44): 33704 - 33716. [Abstract] [Full Text] [PDF] M. Sandherr, H. Einsele, H. Hebart, C. Kahl, W. Kern, M. Kiehl, G. Massenkeil, O. Penack, X. Schiel, S. Schuettrumpf, et al. Antiviral prophylaxis in patients with haematological malignancies and solid tumours: Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Oncology (DGHO) Ann. Onc., July 1, 2006; 17(7): 1051 - 1059. [Abstract] [Full Text] [PDF] B. N. Savani, K. Rezvani, S. Mielke, A. Montero, R. Kurlander, C. S. Carter, S. Leitman, E. J. Read, R. Childs, and A. J. Barrett Factors associated with early molecular remission after T cell-depleted allogeneic stem cell transplantation for chronic myelogenous leukemia Blood, February 15, 2006; 107(4): 1688 - 1695. [Abstract] [Full Text] [PDF] B. M. Ogle, L. J. West, D. J. Driscoll, S. E. Strome, R. R. Razonable, C. V. Paya, M. Cascalho, and J. L. Platt Effacing of the T Cell Compartment by Cardiac Transplantation in Infancy J. Immunol., February 1, 2006; 176(3): 1962 - 1967. [Abstract] [Full Text] [PDF] M. Perreau and E. J. Kremer Frequency, Proliferation, and Activation of Human Memory T Cells Induced by a Nonhuman Adenovirus J. Virol., December 1, 2005; 79(23): 14595 - 14605. [Abstract] [Full Text] [PDF] L. Lenaerts, E. Verbeken, E. De Clercq, and L. Naesens Mouse Adenovirus Type 1 Infection in SCID Mice: an Experimental Model for Antiviral Therapy of Systemic Adenovirus Infections Antimicrob. Agents Chemother., November 1, 2005; 49(11): 4689 - 4699. [Abstract] [Full Text] [PDF] A. R. Welton, E. J. Chesler, C. Sturkie, A. U. Jackson, G. N. Hirsch, and K. R. Spindler Identification of Quantitative Trait Loci for Susceptibility to Mouse Adenovirus Type 1 J. Virol., September 1, 2005; 79(17): 11517 - 11522. [Abstract] [Full Text] [PDF] H. Jalal, D. F. Bibby, J. W. Tang, J. Bennett, C. Kyriakou, K. Peggs, D. Cubitt, N. S. Brink, K. N. Ward, and R. S. Tedder First Reported Outbreak of Diarrhea Due to Adenovirus Infection in a Hematology Unit for Adults J. Clin. Microbiol., June 1, 2005; 43(6): 2575 - 2580. [Abstract] [Full Text] [PDF] P. R. Kinchington, E. G. Romanowski, and Y. Jerold Gordon Prospects for adenovirus antivirals J. Antimicrob. Chemother., April 1, 2005; 55(4): 424 - 429. [Abstract] [Full Text] [PDF] A. M. Leen, U. Sili, E. F. Vanin, A. M. Jewell, W. Xie, D. Vignali, P. A. Piedra, M. K. Brenner, and C. M. Rooney Conserved CTL epitopes on the adenovirus hexon protein expand subgroup cross-reactive and subgroup-specific CD8+ T cells Blood, October 15, 2004; 104(8): 2432 - 2440. [Abstract] [Full Text] [PDF] A. Y. L. Ho, A. Pagliuca, M. Kenyon, J. E. Parker, A. Mijovic, S. Devereux, and G. J. Mufti Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning Blood, September 15, 2004; 104(6): 1616 - 1623. [Abstract] [Full Text] [PDF] A. M. Leen, U. Sili, B. Savoldo, A. M. Jewell, P. A. Piedra, M. K. Brenner, and C. M. Rooney Fiber-modified adenoviruses generate subgroup cross-reactive, adenovirus-specific cytotoxic T lymphocytes for therapeutic applications Blood, February 1, 2004; 103(3): 1011 - 1019. [Abstract] [Full Text] [PDF] W. G. Nichols Management of Infectious Complications in the Hematopoietic Stem Cell Transplant Recipient J Intensive Care Med, November 1, 2003; 18(6): 295 - 312. [Abstract] [PDF] S. Chakrabarti, D. W. Milligan, D. Pillay, S. Mackinnon, K. Holder, N. Kaur, D. McDonald, C. D. Fegan, H. Waldmann, G. Hale, et al. Reconstitution of the Epstein-Barr virus-specific cytotoxic T-lymphocyte response following T-cell-depleted myeloablative and nonmyeloablative allogeneic stem cell transplantation Blood, August 1, 2003; 102(3): 839 - 842. [Abstract] [Full Text] [PDF]

	Copyright © 2002 by American Society of Hematology         Online ISSN: 1528-0020